Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLLLina van der Straten, Mark‐David Levin, Clemens Mellink et al.|Blood|2023Cited by 27
Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemiaArnon P. Kater, Mark‐David Levin, Marinus H. J. van Oers et al.|Haematologica|2018Cited by 13
Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 studyFatemeh Saberi Hosnijeh, Mark‐David Levin, Lina van der Straten et al.|Experimental Hematology|2020Cited by 8